Authors

Latest:

Decoding Developments in GVHD Management With Drs Salhotra and Negrin

Amandeep Salhotra, MD, and Robert Negrin, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in graft-vs-host disease presented during the 2025 ASH Annual Meeting & Exposition.

Neil J. Shah, MBBS

Latest:

Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI Combos

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

Félix Guerrero-Ramos, MD, PhD, FEBU

Guerrero-Ramos is the coordinator of the urologic oncology unit and the bladder cancer unit at Hospital Universitario 12 de Octubre, in Madrid, Spain.

Latest:

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Lucy Gilbert, MD, MSc

Latest:

Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Khalid Matin, MD, FACP

Latest:

Community-Based Programs Have the Power to Remove Clinical Trial Barriers

Homogeneous trials present a missed opportunity to discover treatments that might be highly successful in a particular subset of patients.

Anna T. Levy, DO

Latest:

Dr. Levy on the Safety Profile, Dosing of Cabozantinib in HCC

Anna T. Levy, DO, discuses the safety profile and appropriate dosing of cabozantinib in patients with hepatocellular carcinoma.

Oladapo Yeku, MD, PhD, FACP

Latest:

Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian Cancer

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.

Sponsored Q&A by Dr. Wang

Giuseppe Barbesino, MD

Latest:

Novel Treatment Advances in Differentiated Thyroid Cancer

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Matthew Brunner, MD

Latest:

Dr Brunner on the Heterogeneity of Relapsed Multiple Myeloma

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Dr. Robert Dreicer

Latest:

Assessing the Prostate Cancer Treatment Paradigm: Understanding When to Intensify Treatment

Sponsored Content by Astellas Pharma US, Inc. and Pfizer Inc.; Dr. Dreicer has been compensated for the development of this article.

Matthew A. Lunning, DO, FACP

Latest:

CAR T-cells as Third-line and Beyond Therapy for FL

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Kate Gasparini, PharmD, BCOP, BCPPS

Kate Gasparini, PharmD, BCOP, BCPPS, is a pediatric oncology clinical pharmacy specialist at Memorial Sloan Kettering Cancer Center

Latest:

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphagia

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

Kelsey Pan, MD, MPH

Kelsey Pan, MD, MPH, is the chief hematology/oncology fellow at MD Anderson Cancer Center.

Latest:

Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC

Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.

Christopher Pleyer, MD

Latest:

Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL

Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Cora Sternberg, MD, FACP, Weill Cornell Medicine

Latest:

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

Jane Delartigue, PhD

Latest:

Tumor Agnostic Role of TMB Biomarker Faces Challenges

Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.

Abramson Cancer Center

Latest:

Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.

Jean-Marie Michot, MD

Jean-Marie Michot, MD, is a medical doctor in the Department of Hematology and Innovative Drugs at the Institut de Cancérologie Gustave Roussy.

Latest:

Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL

Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.

Abdul Rafeh Naqash, MD

Latest:

Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC

Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.